Table 4.
Baseline information between the two treatment groups
| CsA + GC | GC | P‐value | |
|---|---|---|---|
| Number | 15 | 10 | |
|
Age (y) Median (range) |
22 (15‐46) | 26.5 (18‐44) | .478 |
|
Disease type Myelogenous/Lymphoid |
6/9 | 5/5 | .697 |
|
Transplant type HRD/MSD/MUD |
8/3/4 | 6/2/2 | .924 |
| Sex ratio (men/women) | 9/6 | 5/5 | .466 |
|
Pretransplant disease state CR/Non‐CR |
11/4 | 7/3 | 1.000 |
|
Stem cell source PBSC/PBSC + BM |
7/8 | 4/6 | .742 |
|
HLA matched Yes/No |
7/8 | 4/6 | .742 |
|
ABO matched Yes/No |
8/7 | 5/5 | 1.000 |
|
Sex matched Yes/No |
7/8 | 7/3 | .414 |
|
ATG/CD25 used Yes/No |
11/4 | 9/1 | .615 |
|
TBI used Yes/No |
10/5 | 6/4 | .734 |
|
CMV viremia Positive/Negative |
10/5 | 3/7 | .111 |
|
aGVHD Yes/No |
7/8 | 4/6 | .742 |
|
cGVHD Yes/No |
7/8 | 10/0 | .008 |
|
AHDs type AIHA/Evans |
9/6 | 9/1 | .179 |
Abbreviations: aGVHD, acute graft vs host disease; AHDs, autoimmune hematological diseases; AIHA, autoimmune hemolytic anemia; ATG, antithymocyte globulin; BM, bone marrow; cGVHD, chronic graft vs host disease; CMV, cytomegalovirus; CsA, cyclosporine A; CR, complete remission; Evans, Evans syndrome; GC, glucocorticoid; HLA, human leukocyte antigen; HRD, haploidentical‐related donor; MSD, matched sibling donor; MUD, matched unrelated donor; PBSCs, peripheral blood stem cells; TBI, total body irradiation.